Alimera Sciences, Inc. (ALIM)
| Market Cap | 36.63M |
| Revenue (ttm) | 58.84M |
| Net Income (ttm) | -1.24M |
| Shares Out | 6.94M |
| EPS (ttm) | -0.20 |
| PE Ratio | n/a |
| Forward PE | 65.79 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 13,285 |
| Open | 5.74 |
| Previous Close | 5.79 |
| Day's Range | 5.25 - 5.80 |
| 52-Week Range | 3.94 - 12.25 |
| Beta | 1.67 |
| Analysts | Strong Buy |
| Price Target | 14.83 (+180.9%) |
| Earnings Date | Oct 28, 2021 |
About ALIM
Alimera Sciences, Inc., a pharmaceutical company, engages in the development and commercialization of prescription ophthalmic pharmaceuticals in the United States and internationally. It offers ILUVIEN, an intravitreal implant for the treatment of diabetic macular edema (DME), which is a disease of the retina that affects individuals with diabetes and could lead to severe vision loss and blindness; and to prevent relapse in recurrent non-infectious uveitis affecting the posterior segment of the eye. The company sells its products to physician o...
Financial Performance
In 2020, ALIM's revenue was $50.82 million, a decrease of -5.79% compared to the previous year's $53.94 million. Losses were -$5.34 million, -48.87% less than in 2019.
Financial StatementsAnalyst Forecast
According to 3 analysts, the average rating for ALIM stock is "Strong Buy." The 12-month stock price forecast is 14.83, which is an increase of 180.87% from the latest price.
News
Alimera Sciences to Participate in Upcoming November 2021 Investor Conferences
ATLANTA, Nov. 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners conce...
Alimera Sciences (ALIM) Reports Q3 Loss, Misses Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -15.38% and -1.20%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences Announces Third Quarter 2021 Financial Results
ATLANTA, Oct. 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company whose mission is to be invaluable to patients, physicians and partners concern...
Alimera Sciences to Report Third Quarter 2021 Financial Results on Thursday, October 28, 2021, and Provide Corporate ...
Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time Conference Call to be held Thursday, October 28, 2021, at 9:00am Eastern Time
Analysts Estimate Alimera Sciences (ALIM) to Report a Decline in Earnings: What to Look Out for
Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Recent 24-Month Real-World PALADIN Data Demonstrate the Ability of ILUVIEN® to Significantly Reduce Treatment Burden ...
PALADIN Study Data Presented at the American Society of Retina Specialists Shows That Post-ILUVIEN, the Percentage of Eyes Receiving One Yearly Treatment or Less Increased 3.2-Fold Compared to Pre-ILUVIEN
Alimera Sciences, Inc. to Present at the H.C. Wainwright 23rd Annual Global Investment Virtual Conference
ATLANTA, Sept. 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a global pharmaceutical company whose mission is to be i...
Alimera Sciences Announces National Pricing and Reimbursement Granted for ILUVIEN® for DME in Belgium
ATLANTA, Aug. 24, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic ...
New Strong Sell Stocks for August 19th
ALIM, BEEM, CDR, ENTX, and IDEX have been added to the Zacks Rank #5 (Strong Sell) List on August 19, 2021.
Alimera Sciences (ALIM) Q2 Earnings and Revenues Miss Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -39.20% and -6.85%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?
Recap: Alimera Sciences Q2 Earnings
Shares of Alimera Sciences (NASDAQ:ALIM) moved higher by 5.3% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 252.94% year over year to $0.78, w...
Alimera Sciences Announces Second Quarter 2021 Financial Results
ATLANTA, Aug. 13, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription opht...
Alimera Sciences to Report Second Quarter 2021 Financial Results on Friday, August 13, 2021, and Provide Corporate Up...
Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time Conference Call to be held Friday, August 13, 2021, at 9:00 am Eastern Time
Alimera Sciences (ALIM) Earnings Expected to Grow: Should You Buy?
Alimera Sciences (ALIM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alimera Sciences, Inc. to Present at the Summer Solstice – Best Ideas from the Buy Side Conference on June 2, 2021
ATLANTA, May 27, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalmic...
Alimera Sciences Appoints David Dyer, M.D. as Chief Retina Specialist
ATLANTA, May 17, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a leader in the commercialization and development of prescription ophthalmic pharmaceuticals, has announced the...
Alimera Sciences (ALIM) Reports Q1 Loss, Lags Revenue Estimates
Alimera Sciences (ALIM) delivered earnings and revenue surprises of -26.00% and -3.33%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?
Alimera Sciences Announces First Quarter 2021 Financial Results
ATLANTA, April 28, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera), a global pharmaceutical company that specializes in the commercialization and development of prescription oph...
Earnings Outlook For Alimera Sciences
On Wednesday, April 28, Alimera Sciences (NASDAQ:ALIM) will report its last quarter's earnings. Here is Benzinga's preview of the company's release.
Alimera Science's Innovative Treatment for Diabetic Macular Edema Vision Loss Lasts for up to 3 Years
Intravitreal Implant Provides a Daily Microdose Release to Reduce Disease Recurrence Amid required stay-at-home orders, many have paused or canceled doctor's appointments over the past 12 months. Rece...
Alimera Sciences Receives $20 Million From Ocumension Therapeutics
ATLANTA, April 14, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic...
Alimera Sciences to Present at the Zooming with LD Micro Virtual Conference on April 15, 2021
ATLANTA, April 09, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalm...
Alimera Sciences to Present at the H.C. Wainwright Global Life Sciences Conference
ATLANTA, March 02, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq: ALIM) (“Alimera”), a pharmaceutical company that specializes in the commercialization and development of prescription ophthalm...
Alimera Sciences Reports Fourth Quarter and 2020 Results
Fourth Quarter Highlights:
Alimera Sciences Continues Global Geographic Expansion With Launch of ILUVIEN in Finland for Both Indications
ATLANTA, Feb. 18, 2021 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (NASDAQ: ALIM) (Alimera), a pharmaceutical company that specializes in the development and commercialization of prescription ophthalmic ...